CEO, Linda Powers to speak on "Novel Personalize Immune Therapies for Solid Tumors"
Linda Powers will discuss Northwest Bio’s DCVax® platform technology, a personalized, dendritic cell based active immunotherapy for solid tumors at this year's 6th annual Cancer Vaccines conference. Unlike conventional cancer drugs and other immune therapies, which use one active agent to hit one target on the cancer, DCVax mobilizes many active agents of the immune system to hit many targets on the cancer. For more information, please visit www.cancervaccinesevent.com/ihub
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.